Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Lipocine Inc. | Director | Stock Option (Right to Buy) | 5.41K | $38.1K | $7.05 | Jun 5, 2024 | Direct |
Vigil Neuroscience, Inc. | Chief Medical Officer | Common Stock | 4K | $15K | $3.75 | Nov 18, 2022 | Direct |
BIONOMICS LIMITED/FI | Chief Executive Officer, Director | Ordinary Shares | 6M | Jul 1, 2024 | Direct | ||
Vigil Neuroscience, Inc. | Chief Medical Officer | Stock Option Grant (Right to Buy) | 150K | Nov 18, 2022 | Direct | ||
Adamas Pharmaceuticals Inc | Director | Common Stock | 0 | $5.16 | Nov 24, 2021 | Direct | |
Adamas Pharmaceuticals Inc | Director | Stock Option (Right to Buy) | 0 | Nov 24, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
BNOX | BIONOMICS LIMITED/FI | Jul 1, 2024 | 0 | $0 | 3 | Jul 8, 2024 | Chief Executive Officer, Director |
LPCN | Lipocine Inc. | Jun 5, 2024 | 1 | $12.4K | 4 | Jun 7, 2024 | Director |
LPCN | Lipocine Inc. | May 10, 2023 | 1 | $7.97K | 4 | May 12, 2023 | Director |
LPCN | Lipocine Inc. | Nov 22, 2022 | 1 | $10.2K | 4 | Nov 28, 2022 | Director |
VIGL | Vigil Neuroscience, Inc. | Nov 18, 2022 | 3 | -$3.63K | 4 | Nov 22, 2022 | Chief Medical Officer |
LPCN | Lipocine Inc. | Jun 8, 2022 | 1 | $20.2K | 4 | Jun 10, 2022 | Director |
VIGL | Vigil Neuroscience, Inc. | May 3, 2022 | 1 | $13.6K | 4 | May 4, 2022 | Chief Medical Officer |
LPCN | Lipocine Inc. | Apr 11, 2022 | 1 | $11.6K | 4 | Apr 12, 2022 | Director |
LPCN | Lipocine Inc. | Apr 11, 2022 | 0 | $0 | 3 | Apr 12, 2022 | Director |
VIGL | Vigil Neuroscience, Inc. | Mar 1, 2022 | 1 | $0 | 4 | Mar 3, 2022 | Chief Medical Officer |
VIGL | Vigil Neuroscience, Inc. | Jan 6, 2022 | 0 | $0 | 3 | Jan 6, 2022 | Chief Medical Officer |
ADMS | Adamas Pharmaceuticals Inc | Nov 24, 2021 | 3 | $0 | 4 | Nov 24, 2021 | Director |
ADMS | Adamas Pharmaceuticals Inc | Jun 2, 2021 | 2 | $0 | 4 | Jun 4, 2021 | Director |